1-苯基-N-丙基戊基-2-胺 | 119485-94-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苯基-N-丙基戊基-2-胺
• 英文名称: N-propyl-1-phenyl-2-pentylamine
• 英文别名: (1-Phenylpentan-2-yl)(propyl)amine；1-phenyl-N-propylpentan-2-amine
• CAS: 119485-94-8
• 化学式: C₁₄H₂₃N
• mdl: MFCD00872422
• 分子量: 205.343
• InChiKey: PBENSVGEGPJNFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  290.5±9.0 °C(Predicted)
• 密度：
  0.890±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.571
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  1-苯基-2-戊酮 在 正丙胺 、 sodium borohydrid 、 无水氯化钙 作用下， 以 甲醇 、 水 、 苯 为溶剂， 生成 1-苯基-N-丙基戊基-2-胺
  参考文献：
  名称：

  Method of treatment of learning deficiency

  摘要：

  揭示了一种治疗学习缺陷的方法，其中需要刺激学习能力的患者接受治疗，治疗剂量为化合物的有效量，该化合物的化学式为（I）其中R.sup.1为C.sub.1至C.sub.8直链或支链烷基，C.sub.7至C.sub.10苯基烷基，苯基或C.sub.3至C.sub.8环烷基；R.sup.2为C.sub.1至C.sub.8直链或支链烷基，未取代或由卤素、羟基、C.sub.1至C.sub.4烷氧基或1或2苯基取代；或为C.sub.3至C.sub.8环烷基；但R.sup.1和R.sup.2至少含有3个碳原子；或其药用盐。

  公开号：

  US05075338A1

文献信息

• Regioselective Preparation of 2-Phenylethylamines from 1-Phenyl-2-alkyl­alkynes by Hydroamination/Reduction Sequences
  作者：Sven Doye、Andreas Heutling、René Severin

  DOI：10.1055/s-2004-834863

  日期：——

  Ind2TiMe2 is a highly active and general catalyst for the intermolecular hydroamination of alkynes. Particularly impressive is that Ind2TiMe2 makes it possible to perform hydroamination reactions of unsymmetrically substituted 1-phenyl-2-alkylalkynes with primary aryl-, tert-alkyl-, sec-alkyl-, and n-alkylamines in a highly regioselective fashion. Since the initially formed imines can easily be reduced with zinc-modified NaBH3CN, 2-phenylethylamines are accessible in reliable one-pot procedures from 1-phenyl-2-alkylalkynes and primary amines on a 10 mmol scale.

  Ind2TiMe2 是炔烃分子间氢化反应的高活性通用催化剂。尤其令人印象深刻的是，Ind2TiMe2 能够以高度区域选择性的方式使不对称取代的 1-苯基-2-烷基炔与伯芳基、叔烷基、仲烷基和正烷基胺发生氢化反应。由于最初形成的亚胺可以很容易地用锌改性的 NaBH3CN 还原，因此可以在 10 毫摩尔的规模上通过可靠的一锅法从 1-苯基-2-烷基炔和伯胺中获得 2-苯基乙胺。
• Psychostimulant agent
  申请人：Chinoin Gyogyszer - es Vegyeszeti Termekek Gyara Rt.

  公开号：US05220068A1

  公开（公告）日：1993-06-15

  The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms; R.sup.2 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; alkyl comprising 1 to 8 carbon atoms substituted by halogen, hydroxy, alkoxy having 1 to 4 carbon atoms or by one or two phenyl groups; phenyl; or cycloalkyl having 3 to 8 carbon atoms, with the proviso that groups R.sup.1 and R.sup.2 together contain at least three carbon atoms. The invention also relates to a process for the preparation of compounds of the Formula I by methods known per se. The compounds of the Formula I are phychostimulants having a new spectrum of effect which can be used in therapy for increasing psychical activity (learning and retention) and for treating clinical patterns of depression and deficiencies of learning and retention like in Alzheimer's disease, and are void of side effects (e.g. due to catecholamine release) of known stimulants.

  本发明涉及一种药物组合物，其活性成分为式I的化合物，其中R1代表直链或支链烷基，包括1到8个碳原子;含有7到10个碳原子的苯基烷基;苯基;或包含3到8个碳原子的环烷基；R2代表直链或支链烷基，包括1到8个碳原子；1到8个碳原子被卤素、羟基、1到4个碳原子的烷氧基或一个或两个苯基取代的烷基；苯基；或含有3到8个碳原子的环烷基，但要求R1和R2组合至少含有三个碳原子。本发明还涉及一种通过已知方法制备式I化合物的方法。式I化合物是具有新的作用谱的兴奋剂，可用于增加心理活动（学习和记忆）的治疗和治疗临床抑郁症和学习和记忆缺陷，如阿尔茨海默病，且没有已知兴奋剂的副作用（例如由于儿茶酚胺释放）。
• NOVEL ETHYLAMINE DERIVATIVES
  申请人：Fujimoto Brothers Co., Ltd.

  公开号：EP0957080A1

  公开（公告）日：1999-11-17

  General formula (I):    (wherein R1 is hydrogen, hydroxyl, lower alkoxy or halogen; R2 is alkyl having 2 to 5 carbon atoms; R3 is hydrogen, alkyl having 2 to 5 carbon atoms, alkylcarbonyl having 2 to 5 carbon atoms, aryl having 6 to 10 carbon atoms or arylalkyl having 7 to 11 carbon atoms; A ring is bicyclic compound which consists of at least one benzene ring and may contain a saturated or unsaturated five- or six-membered ring which may or my not have heteroatoms, providing that when A ring is indole or 1,3-benzodioxole, R2 and R3 do not constitute, at the same time, two carbon atoms members, and when R3 is hydrogen. A ring is other bicyclic compound than indole and benzo[b]thiophene and R2 is alkyl having 3 to 5 carbon atoms) and pharmceutically acceptable acid addition salts thereof. These compounds are promising as psychtropic drugs, antidepressants, drugs for Parkinson's disease and/or drugs for Alzheimer's disease.

  通式（I）： (其中 R1 是氢、羟基、低级烷氧基或卤素；R2 是具有 2 至 5 个碳原子的烷基；R3 是氢、具有 2 至 5 个碳原子的烷基、具有 2 至 5 个碳原子的烷羰基、具有 6 至 10 个碳原子的芳基或具有 7 至 11 个碳原子的芳烷基；环是双环化合物，由至少一个苯环组成，可包含饱和或不饱和的五元或六元环，可带或不带杂质原子，条件是当环是吲哚或 1,3-苯并二恶茂时，R2 和 R3 不同时构成两个碳原子成员，且当 R3 为氢时。环是吲哚和苯并[b]噻吩以外的其他双环化合物，R2 是具有 3 至 5 个碳原子的烷基）及其药学上可接受的酸加成盐。这些化合物有望成为精神药物、抗抑郁药物、帕金森病药物和/或阿尔茨海默病药物。
• Compounds for use in the prevention or treatment of cancer
  申请人：SEMMELWEIS UNIVERSITY

  公开号：US10258598B2

  公开（公告）日：2019-04-16

  The invention relates to the field of prevention and treatment of cancer, in particular suppression of tumor manifestation. The invention also relates to compounds for use in this field. A novel tumor manifestation suppression (TMS) regulation in a mammalian brain is recognized. The invention relates to compounds, pharmaceutical preparations, in particular medicaments for use in the prevention and treatment of cancer, in particular suppression of tumor manifestation based on said TMS regulation as well as methods for the same.

  本发明涉及癌症的预防和治疗领域，特别是抑制肿瘤的表现。本发明还涉及用于该领域的化合物。本发明确认了一种新型的哺乳动物大脑肿瘤表现抑制（TMS）调节方法。本发明涉及化合物、药物制剂，特别是用于预防和治疗癌症的药物，尤其是基于所述TMS调节的肿瘤表现抑制以及相关方法。
• Structure–activity studies leading to (−)1-(Benzofuran-2-yl)-2-propylaminopentane, ((−)BPAP), a highly potent, selective enhancer of the impulse propagation mediated release of Catecholamines and Serotonin in the brain
  作者：F Yoneda

  DOI：10.1016/s0968-0896(01)00002-5

  日期：2001.5

  The catecholaminergic and serotoninergic neurons in the brain change their performance according to the physiological need via a catecholaminergic/serotoninergic activity enhancer (CAE/SAE) mechanism. Phenylethylamine (PEA), tyramine and tryptamine are the presently known endogenous CAE/SAE substances which enhance the impulse propagation mediated release of catecholamines and serotonin in the brain. A PEA derivative, (-)deprenyl (selegiline), known as a selective inhibitor of MAO-B, is for the time being the only CAE/SAE substance in clinical use. Aiming to develop a selective CAE/SAE substance much more potent than (-)deprenyl, a series of new 1-aryl-2-alkylaminoalkanes, structurally unrelated to PEA and the amphetamines, was designed and prepared. Among them, (-)1-(benzofuran-2-yl)-2-propylaminopentane ((-)BPAP) was selected as a promising candidate substance for further studies. (-)BPAP significantly enhanced in rats the impulse propagation mediated release of catecholamines and serotonin in the brain 30 min after acute injection of 0.36 nmol/kg sc. In the shuttle box, (-)BPAP was in rats about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance. (-)BPAP protected cultured hippocampal neurons from the neurotoxic effect of P-amyloid in 10(-14)-10(-15) concentration. (C) 2001 Elsevier Science Ltd. All rights reserved.